

Linden is a Senior Portfolio Manager at Candriam, managing biotechnology and oncology strategies since 2024.
Prior to joining Candriam, she was the lead manager of a biotech fund at AXA IM as well as the head of their healthcare franchise and a member of the UK Executive Committee. She brings over two decades of buy-side and sell-side experience in biotechnology. Linden started her career at Goldman Sachs in 2003, establishing technical expertise in healthcare, before moving on to a biotech hedge fund at start-up stage and subsequently to AXA Investment Managers in 2011.
Linden holds a BS (Hons) in Medical Microbiology from the University of Edinburgh. She has been a CFA Charterholder since 2011.
Discover the latest articles by Linden Thomson, CFA

ESG, SRI, Healthcare, Servaas Michielssens, Linden Thomson
Healthcare share prices tend to reflect some trepidation leading up to and shortly after the US presidential elections, yet for the last five elections the sector outperformed in the 12 months following the election.

Oncology, Q&A, Servaas Michielssens, Linden Thomson, Equities
Investing in oncology: forewarned is forearmed
Servaas Michielssens and Linden Thomson explain to investors the approach they used to create and develop an investment strategy in the oncology sector.